Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon therapy in multiple myeloma].

H Ludwig1, W Scheithauer, I Kührer

  • 1II. Medizinische Universitätsklinik, Wien.

Onkologie
|August 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care-a tale stretching over 8 years.

ESMO open·2023
Same author

COP27 Climate Change Conference: urgent action needed for Africa and the world.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Introducing pro and con discussions in ESMO Open-Cancer Horizons.

ESMO open·2022
Same author

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit.

ESMO open·2022
Same author

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.

ESMO open·2021

Interferon therapy shows 10-20% remission in multiple myeloma, with better results in early-stage or untreated patients. Combination therapy appears safe but requires further study for improved response rates.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Multiple myeloma is a hematologic malignancy.
  • Interferon therapy has been explored for multiple myeloma treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of interferon therapy in multiple myeloma.
  • To identify patient subgroups that may benefit more from interferon treatment.
  • To assess the potential of combined interferon-chemotherapy regimens.

Main Methods:

  • Analysis of remission and response rates in patients treated with natural leukocyte interferon and recombinant interferon alpha-2.
  • Comparison of response rates between untreated and relapsed/refractory multiple myeloma patients.
  • Evaluation of patient characteristics associated with increased interferon sensitivity.

Related Experiment Videos

  • Review of initial trials combining interferon with chemotherapy.

    • Main Results:

    • Interferon achieved 10-20% remission rates in multiple myeloma.
    • Higher response rates were observed in untreated patients compared to relapsing or refractory cases.
    • Patients with slowly proliferating tumors, early stage, or IgA-monoclonal protein showed greater sensitivity.
    • Initial combination therapy trials indicated acceptable toxicity.

    Conclusions:

    • Interferon therapy offers a modest remission rate for multiple myeloma, particularly in specific patient groups.
    • Combined interferon-chemotherapy regimens show promise with acceptable safety.
    • Further research is needed to confirm the benefits of combination therapy in improving response rates.